Saltar al contenido
Dispositivos y mediciónEstudio de cohorte4 min read

Only 27.4% of arthritis patients met WHO activity targets on a tracker

Colectivo editorial MoveVitals · Study published · Reading updated

Original paper:Physical Activity Assessment Using an Activity Tracker in Patients with Rheumatoid Arthritis and Axial Spondyloarthritis: Prospective Observational Study. · JMIR mHealth and uHealth · 2018 · Artículo original ↗

Idea principal

Among 157 patients with rheumatoid arthritis (83) or axial spondyloarthritis (74) tracked for 3 months, only 27.4% (43/157) reached the WHO target of 150 minutes per week of moderate to vigorous activity, and the two diseases had similar levels. Participants all owned smartphones and joined a research study, so they may be more active and tech-ready than typical patients.

Study design

Estudio de cohorte

Reading basis

Published abstract

Reading focus

Association & confounding

Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.

Pregunta de investigación

Physical activity is recommended in managing rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA), and mobile devices can track it, but little is known about how active these patients really are. The authors measured and compared activity levels and patterns in RA and axSpA with a tracker, and checked whether wearing one is feasible for these patients.

Población y método

Multicentre prospective observational study (ActConnect) of patients with definite RA or axSpA who owned a smartphone. Activity was recorded over 3 months with a mobile activity tracker counting steps per minute. The authors counted how many patients met the WHO recommendation of at least 150 min per week of moderate to vigorous physical activity (MVPA). RA and axSpA were compared with linear mixed models for steps, proportion of morning steps, total activity duration and MVPA. Activity trajectories were identified with the K-means method, and factors linked to low activity were explored with logistic regression. Acceptability was judged by days of wear, percentage of wearing time and a questionnaire.

Resultados

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    157 patients were analysed (83 RA, 74 axSpA); 36.3% (57/157) were men, mean age 46 years (SD 12) and mean disease duration 11 years (SD 9).
  2. 2
    MVPA was similar in the two diseases: 16 min per day (SD 11) in RA and 15 min per day (SD 12) in axSpA (P = .80).
  3. 3
    Only 27.4% (43/157) reached the WHO recommendation, with a mean MVPA of 106 min per week (SD 77).
  4. 4
    Three stable activity trajectories emerged: low (54.1%, 85/157), moderate (42.7%, 67/157) and high (3.2%, 5/157) levels of MVPA. A higher BMI was significantly related to less activity (odds ratio 1.12, 95% CI 1.11-1.14).
  5. 5
    Trackers were worn a mean of 79 days (SD 17) out of 90 days, and patients rated acceptability at a mean of 8 out of 10.

Límites e incertidumbre

  1. 1
    Participants needed a smartphone and agreed to join a 3-month study, so they may differ from typical patients with these diseases.
  2. 2
    Observational design with no comparison group without arthritis, so the study cannot say how patients' activity compares with healthy people.
  3. 3
    A tracker's minutes of moderate to vigorous activity are estimates, and the abstract does not name the device or validate its accuracy in people with joint problems.
  4. 4
    Only 5 patients fell in the high-activity trajectory, which limits conclusions about that group, and this reading is based on the abstract only.

Relevancia práctica

People with RA or axSpA in this study were mostly less active than guidelines suggest, but the study did not test whether becoming more active improves their symptoms. Wearing an activity tracker for months was feasible and well accepted. Exercise advice that suits your joints and disease activity should come from your rheumatology team.

Tus datos

This is directly relevant to wearables: weekly minutes of moderate to vigorous activity and daily steps are what the study tracked. Compare your own weeks on the same device and wear pattern, rather than judging single days, and remember that devices estimate intensity less accurately than they count steps.

Cómo interpretar la evidencia

Exposure precedes follow-up outcomes, but confounding and reverse causation can remain. A hazard ratio is not an individual absolute risk or a demonstrated intervention effect.

Resumen estructurado de los autores English

El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.

Background

Physical activity can be tracked using mobile devices and is recommended in rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA) management. The World Health Organization (WHO) recommends at least 150 min per week of moderate to vigorous physical activity (MVPA).

Objective

The objectives of this study were to assess and compare physical activity and its patterns in patients with RA and axSpA using an activity tracker and to assess the feasibility of mobile devices in this population.

Methods

This multicentric prospective observational study (ActConnect) included patients who had definite RA or axSpA, and a smartphone. Physical activity was assessed over 3 months using a mobile activity tracker, recording the number of steps per minute. The number of patients reaching the WHO recommendations was calculated. RA and axSpA were compared, using linear mixed models, for number of steps, proportion of morning steps, duration of total activity, and MVPA. Physical activity trajectories were identified using the K-means method, and factors related to the low activity trajectory were explored by logistic regression. Acceptability was assessed by the mean number of days the tracker was worn over the 3 months (ie, adherence), the percentage of wearing time, and by an acceptability questionnaire.

Results

A total of 157 patients (83 RA and 74 axSpA) were analyzed; 36.3% (57/157) patients were males, and their mean age was 46 (standard deviation [SD] 12) years and mean disease duration was 11 (SD 9) years. RA and axSpA patients had similar physical activity levels of 16 (SD 11) and 15 (SD 12) min per day of MVPA (P=.80), respectively. Only 27.4% (43/157) patients reached the recommendations with a mean MVPA of 106 (SD 77) min per week. The following three trajectories were identified with constant activity: low (54.1% [85/157] of patients), moderate (42.7% [67/157] of patients), and high (3.2% [5/157] of patients) levels of MVPA. A higher body mass index was significantly related to less physical activity (odds ratio 1.12, 95% CI 1.11-1.14). The activity trackers were worn during a mean of 79 (SD 17) days over the 90 days follow-up. Overall, patients considered the use of the tracker very acceptable, with a mean score of 8 out 10.

Conclusions

Patients with RA and axSpA performed insufficient physical activity with similar levels in both groups, despite the differences between the 2 diseases. Activity trackers allow longitudinal assessment of physical activity in these patients. The good adherence to this study and the good acceptability of wearing activity trackers confirmed the feasibility of the use of a mobile activity tracker in patients with rheumatic diseases.

Fuentes y atribución

Physical Activity Assessment Using an Activity Tracker in Patients with Rheumatoid Arthritis and Axial Spondyloarthritis: Prospective Observational Study.

Jacquemin C, Servy H, Molto A, Sellam J, Foltz V, Gandjbakhch F, Hudry C, Mitrovic S, Fautrel B, Gossec L.

JMIR mHealth and uHealth · 2018-01-02

DOI: 10.2196/mhealth.7948 ↗PubMed · 29295810 ↗Europe PMC · Licencia registrada: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada

Fuentes verificadas 2026-11-01

Guías prácticas

Leer en contexto

·Estudio de cohorte

Activity–stroke and heart attack curves differ by accelerometer processing method

Among 90,237 UK Biobank adults free of cardiovascular disease at baseline, followed until December 2022 for 1,298 strokes and 2,031 myocardial infarctions, the shape of the link between moderate-vigorous physical activity (MVPA) and each outcome depended on how the accelerometer data were processed. For stroke, hazard fell in a straight line only with the machine-learning metric; for myocardial infarction, two metrics gave a curved decline and activity counts a straight one. The abstract gives no hazard ratios, so it shows that methods disagree, not which one is right, and the findings are observational associations.

Preventive Medicine

Explicaciones detalladasLeer estudio →
·Estudio/revisión de validación

Smartwatch data as forensic evidence: heart rate is best validated, the rest uneven

A systematic review and meta-analysis of studies on smartwatches from four major brands, framed around digital forensics, found that heart rate was both the most studied and the most accurate measure. Step count, distance, energy expenditure, activity classification and sleep were less consistently validated, and results varied by brand, protocol and reporting. The abstract gives no pooled numbers, and most studies were run in healthy people in laboratories, so it cannot say how a particular watch performs for a particular person in daily life.

Forensic Science International

Explicaciones detalladasLeer estudio →
·Revisión de revisiones

Activity trackers: about 1,800 more steps a day, but small effects on other outcomes

An umbrella review of 39 systematic reviews and meta-analyses, covering 163,992 participants, found that activity trackers were associated with more physical activity (SMD 0.3–0.6), equating to about 1,800 extra steps and 40 minutes more walking per day, and with a bodyweight reduction of about 1 kg. Effects on blood pressure, cholesterol, glycosylated haemoglobin, quality of life and pain were typically small and often non-significant. The abstract does not say what else came with the trackers in these programs or how much the reviews overlap, so the gains cannot be credited to the device alone.

The Lancet Digital Health

Explicaciones detalladasLeer estudio →
·Estudio/revisión de validación

Seven sleep trackers: good at spotting sleep, weak on wake and sleep stages

In a sleep laboratory, 34 healthy young adults wore a subset of seven consumer sleep trackers for three nights. Against polysomnography every device detected sleep very well (sensitivity 0.93 or higher) but caught wake poorly (specificity 0.18–0.54), and five of the seven matched or beat research actigraphy (specificity 0.39). Sleep-stage estimates were inconsistent, and the participants were healthy adults aged 18 to 35 in a fixed 8-hour bed window, with each device tested in only 11 to 20 of them, so the results say little about people with sleep problems.

Sleep

Explicaciones detalladasLeer estudio →
Dispositivos y medición →